155 related articles for article (PubMed ID: 1327702)
1. [Relationship between serum CA125 level and second-look findings in ovarian cancers].
Liu LY
Zhonghua Zhong Liu Za Zhi; 1992 Jul; 14(4):287-9. PubMed ID: 1327702
[TBL] [Abstract][Full Text] [Related]
2. [Second-look laparotomy in epithelial ovarian cancer: an evaluation of 23 cases].
Liu LY
Zhonghua Fu Chan Ke Za Zhi; 1990 Mar; 25(2):77-9, 123. PubMed ID: 2364794
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of second-look laparotomy for ovarian cancer: second-look vs. serum CA125.
Liu L; Hong W; Hou Y; Yao Z; Wu A; Wang X
Chin Med Sci J; 1991 Jun; 6(2):96-9. PubMed ID: 1804384
[TBL] [Abstract][Full Text] [Related]
4. The trend of serum CA125 levels during the first three courses of chemotherapy as a predictor of second-look findings in patients with ovarian carcinoma.
Gadducci A; Ferdeghini M; Bartolini T; Facchini V; Mariani G; Bianchi R; Fioretti P
J Nucl Med Allied Sci; 1989; 33(3):243-6. PubMed ID: 2778499
[TBL] [Abstract][Full Text] [Related]
5. Second-look laparotomy in stage III epithelial ovarian cancer: clinical variables associated with disease status.
Berek JS; Hacker NF; Lagasse LD; Poth T; Resnick B; Nieberg RK
Obstet Gynecol; 1984 Aug; 64(2):207-12. PubMed ID: 6539884
[TBL] [Abstract][Full Text] [Related]
6. Secondary cytoreductive surgery at second-look laparotomy in advanced ovarian cancer: a Gynecologic Oncology Group Study.
Williams L; Brunetto VL; Yordan E; DiSaia PJ; Creasman WT
Gynecol Oncol; 1997 Aug; 66(2):171-8. PubMed ID: 9264559
[TBL] [Abstract][Full Text] [Related]
7. Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients.
Obermair A; Sevelda P
Acta Obstet Gynecol Scand; 2001 May; 80(5):432-6. PubMed ID: 11328220
[TBL] [Abstract][Full Text] [Related]
8. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
9. Relationship of serum CA125 and lipid-associated sialic acid tumor-associated antigen levels to the disease status of patients with gynecologic malignancies.
Stratton JA; Rettenmaier MA; Phillips HB; Herabutya S; DiSaia PJ
Obstet Gynecol; 1988 Jan; 71(1):20-6. PubMed ID: 2827081
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of CA 125 assay system and its diagnostic significance in gynecologic tumors].
Shimizu Y; Akagaki E; Hirota K; Kono M; Miura S; Okudaira Y
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Dec; 37(12):2813-20. PubMed ID: 3866801
[TBL] [Abstract][Full Text] [Related]
11. Is there a role for second-look laparotomy in the management of malignant germ cell tumors of the ovary? Experience at Institut Gustave Roussy.
Culine S; Lhomme C; Michel G; Leclere J; Duvillard P; Droz JP
J Surg Oncol; 1996 May; 62(1):40-5. PubMed ID: 8618400
[TBL] [Abstract][Full Text] [Related]
12. The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer.
Alvarez Secord A; Sayer R; Snyder SA; Broadwater G; Rodriguez GC; Berchuck A; Blackwell K
Gynecol Oncol; 2004 Jul; 94(1):74-9. PubMed ID: 15262122
[TBL] [Abstract][Full Text] [Related]
13. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
[TBL] [Abstract][Full Text] [Related]
14. [The clinical significance of CA125 in patients with gynecological tumors--a comparative study on CA125 and other tumor markers].
Suzumori K; Yasui Y; Asai H; Hisaoka T; Mizuno K; Yagami Y
Gan No Rinsho; 1985 May; 31(5):544-8. PubMed ID: 3860666
[TBL] [Abstract][Full Text] [Related]
15. [Serum CA 125 values and histologic findings at the time of second-look laparotomy in ovarian cancer].
Meier W; Stieber P; Fateh-Moghadam A; Eiermann W; Hepp H
Geburtshilfe Frauenheilkd; 1988 May; 48(5):331-3. PubMed ID: 3165078
[TBL] [Abstract][Full Text] [Related]
16. [Relationship between serum levels and immunohistological tissue levels of CA 125 and CEA in epithelial ovarian cancers: its implications for tumor cell type specificity].
Oishi T; Maruo T; Iwasaki M; Mochizuki M
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Sep; 38(9):1595-604. PubMed ID: 3464659
[TBL] [Abstract][Full Text] [Related]
17. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.
Gadducci A; Ferdeghini M; Malagnino G; Prontera C; Fanucchi A; Annicchiarico C; Bianchi R; Fioretti P; Facchini V
Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196
[TBL] [Abstract][Full Text] [Related]
18. [Clinical value of a new serum tumor marker CA602 in ovarian cancers].
Suzuki M; Sekiguchi I; Ohwada M; Aida I; Tamada T
Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1454-60. PubMed ID: 2170549
[TBL] [Abstract][Full Text] [Related]
19. [The indications for second-look laparotomy in ovarian cancer patients].
Gulo EI; Vinokurov VL; Bokhman IaV
Vopr Onkol; 1992; 38(5):616-23. PubMed ID: 1300762
[TBL] [Abstract][Full Text] [Related]
20. What is a normal CA125 level?
Alagoz T; Buller RE; Berman M; Anderson B; Manetta A; DiSaia P
Gynecol Oncol; 1994 Apr; 53(1):93-7. PubMed ID: 8175027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]